Clinical trial condition

NSCLC

Explore clinical trials studying NSCLC. Study availability and eligibility vary by location and protocol.

357 public trials 121 recruiting studies

Refine in advanced search Browse all conditions

NSCLC trial results

Not Yet Recruiting

Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)

NCT06502249

Conditions: Lung Cancer, Lung Diseases, Lung Neoplasms, +6 more
Locations: Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab Cairo, Egypt

View Trial Details

Not Yet Recruiting

The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

NCT06496009

Conditions: NSCLC
Locations: Not specified

View Trial Details

Not Yet Recruiting

SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

NCT06480136

Conditions: NSCLC
Locations: Not specified

View Trial Details

Not Yet Recruiting

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NCT06465238

Conditions: NSCLC
Locations: Henan cancer hospital Zhengzhou, Henan, China

View Trial Details

Not Yet Recruiting

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

NCT06414915

Conditions: NSCLC
Locations: Not specified

View Trial Details

Not Yet Recruiting

Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer

NCT06329648

Conditions: NSCLC
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

NCT06182761

Conditions: NSCLC
Locations: Not specified

View Trial Details

Not Yet Recruiting

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

NCT05988697

Conditions: Advanced Cancer, BRAF V600E Mutation, Bronchial Neoplasms, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NCT06054191

Conditions: BRAF V600 Mutation, MET Exon 14 Mutation, NSCLC
Locations: Cancer Center of Sun-Yat Sen University Guangzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NCT05778149

Conditions: Anlotinib, Aumolertinib, EGFR Activating Mutation, +2 more
Locations: Not specified

View Trial Details

NSCLC

NSCLC trial results

Related conditions